During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center (DKFZ), the Berlin Institute of Health ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer of the blood—also known as hematologic cancer. It affects cells called plasma cells, which are types of white blood ...

The analysis of 11,427 Veterans Administration (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 ...

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The Bells of Hope community provides support and inspiration, fostering unity ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each ...